US EditionPublished • loading... • Updated
ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
IBI3003 showed an 83.3% overall response rate at doses ≥120 µg/kg with manageable safety in heavily pretreated relapsed/refractory multiple myeloma patients, including high-risk cases.
- Innovent Biologics presented initial Phase 1 data for IBI3003, a trispecific antibody, showing an 83.3% response rate at ≥120 µg/kg at the ASH Annual Meeting.
- Designed to overcome single‑antigen escape, IBI3003 dual-targets BCMA and GPRC5D, and the Phase 1/2 clinical trial is enrolling heavily pretreated R/R MM patients in China and Australia.
- Biomarker and response data show 100% MRD negativity among patients achieving CR or better; CRS occurred in 64.1% and ICANS in 6.1%.
- Under the study rules, eligible patients may switch to Q2W maintenance, while dose optimization remains ongoing in the Phase 1 study, with median follow‑up 3.25 months limiting long‑term conclusions.
- Patients enrolled were heavily pretreated and high‑risk, with median age 62, 64.1% mSMART high‑risk classification, 46.2% extramedullary disease, median prior lines of therapy 4, and 76.9% refractory to last treatment.
Insights by Ground AI
33 Articles
33 Articles
The Billings Gazette+32 Reposted by 32 other sources
ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
SAN FRANCISCO and SUZHOU, China, Dec. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major…
·Billings, United States
Read Full ArticleCoverage Details
Total News Sources33
Leaning Left1Leaning Right1Center16Last UpdatedBias Distribution89% Center
Bias Distribution
- 89% of the sources are Center
89% Center
C 89%
Factuality
To view factuality data please Upgrade to Premium
